Epilepsy News and Research

Latest Epilepsy News and Research

Project Lifesaver International, Xanboo to offer medical facilities to help people with cognitive disorder

Project Lifesaver International, a non-profit organization specializing in training public safety agencies on search and rescue programs to help individuals with cognitive conditions that wander, announced today they will be teaming with Xanboo, a wireless equipment company that supplies a wide variety of intrusion and security products, including indoor and outdoor cameras, control of lighting, door/window censors, and other security products.

5 Feb 2010

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

Paloma Pharmaceuticals, Inc. announced today that it has received acceptance of its IND to enter Phase I studies with Palomid 529 (P529) in patients with age-related macular degeneration (AMD).

5 Feb 2010

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

Alkermes, Inc. today announced that it has developed a novel, proprietary LinkeRx™ technology platform to enable the creation of injectable extended-release versions of antipsychotics and other central nervous system (CNS) therapies.

4 Feb 2010

Immigrants may be healthier than long-term residents

New immigrants to North America may be less likely to have a stroke at a young age than long-time residents, according to a study published in the February 3, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

4 Feb 2010

FDA approves Xiaflex drug for treatment of Dupuytren's contracture

The U.S. Food and Drug Administration (FDA) has approved Xiaflex, a new drug to treat Dupuytren's contracture (or disease) that was discovered and developed by Marie A. Badalamente, Ph.D., and Lawrence C. Hurst, M.D., in the Department of Orthopaedics at Stony Brook University Medical Center.

4 Feb 2010

Phase 2a clinical trial results of VX-809 in patients with CF announced

Vertex Pharmaceuticals Incorporated today announced results from a preliminary analysis of data from a 28-day Phase 2a clinical trial of VX-809 in patients with cystic fibrosis (CF) who are homozygous for the F508del mutation.

4 Feb 2010

Ambassadors of Purple selected to help promote Purple Day for Epilepsy

As the third annual, worldwide Purple Day for Epilepsy approaches on March 26, 2010, organizers in Canada and in 15 other participating countries around the globe are looking for volunteers to promote epilepsy awareness in local communities.

3 Feb 2010

FDA approves Taro Pharmaceutical Industries' levetiracetam tablets ANDA

Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (“ANDA”) for Levetiracetam Tablets, 250 mg, 500 mg, 750 mg and 1000 mg (“levetiracetam tablets”).

2 Feb 2010

Researchers explore how brain circuitry and learning changes over time

New research shows our brains are a lot more chaotic than previously thought, and that this might be a good thing. Neurobiologists at the University of Maryland have discovered information about how the brain processes sound that challenges previous understandings of the auditory cortex, which had suggested an organization based on precise neuronal maps.

2 Feb 2010

Government cracks down on drug marketing

Recent crackdown on pharmaceutical companies suggests that drug marketing remains an issue with federal authorities. The Wall Street Journal reports: "Novartis AG's agreement to settle criminal allegations involving marketing of an epilepsy drug is the latest in a string of cases showing that improper marketing practices are still a problem years after the U.S. government started cracking down on them.

30 Jan 2010

GlaxoSmithKline's Lamictal XR Extended-Release Tablets receive FDA approval

laxoSmithKline announced today that the U.S. Food and Drug Administration has approved Lamictal®XR™ (lamotrigine) Extended-Release Tablets as once-a-day, add-on therapy for epilepsy in patients ages 13 years and older with primary generalized tonic-clonic seizures.

29 Jan 2010

Researchers use sophisticated brain-imaging techniques to predict Alzheimer's before symptoms appear

Estimates are that some 10 percent of people over the age of 65 will develop Alzheimer's disease, the scourge that robs people of their memories and, ultimately, their lives.

29 Jan 2010

UCLA researchers predict brain's progression to Alzheimer's before symptoms are visible

Estimates are that some 10 percent of people over the age of 65 will develop Alzheimer's disease, the scourge that robs people of their memories and, ultimately, their lives.

29 Jan 2010

UCLA's non-invasive pre-surgical testing approach leads to seizure-free surgical outcome in TSC patients

When medication fails to control seizures in children with tuberous sclerosis complex (TSC), a rare genetic disorder that affects multiple organ systems and frequently causes epilepsy, surgery to remove part of the brain is often necessary. But pre-surgical testing, which involves the implanting of electrodes into a child's head, can lead to longer hospital stays and greater risks from surgery.

29 Jan 2010

Patients with epilepsy who take Ginkgo herbal medicines face increased risk of seizures

Restrictions should be placed on the use of Ginkgo biloba (G. biloba) - a top-selling herbal remedy - because of growing scientific evidence that Ginkgo may increase the risk of seizures in people with epilepsy and could reduce the effectiveness of anti-seizure drugs, a new report concludes.

28 Jan 2010

Sepracor's STEDESA NDA: FDA extends PDUFA action date

Sepracor Inc. today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency now anticipates completing its review of the STEDESA™ (eslicarbazepine acetate) New Drug Application (NDA) on April 30, 2010, which is a three-month extension to the original Prescription Drug User Fee Act (PDUFA) date of January 30, 2010.

28 Jan 2010

Large research gap exists in effectiveness, mechanism and safety of drugs in children

Only a few anti-spasticity medications used for children with cerebral palsy are backed by sufficient research to justify their use, according to a new review of scientific literature headed by a UT Southwestern Medical Center neurologist and conducted by a national panel of interdisciplinary experts nationwide.

27 Jan 2010

US PTO grants new allowances to intellectual property covering Neurologix' GAD based delivery systems

Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix’s Parkinson’s disease program. The new allowances to U.S. Patent Number 765,446, entitled “Glutamic acid decarboxylase (GAD) based delivery systems,” broaden the patent’s coverage beyond Parkinson’s disease to include the use of GAD65 in the treatment of other neurological and related disorders.

27 Jan 2010

Depomed plans additional Serada Phase 3 trial for treatment of menopausal hot flashes

Depomed, Inc. announced today it has received guidance from the FDA in formal meeting minutes from a meeting held in December regarding SeradaTM, the company’s extended release gabapentin product candidate for the treatment of menopausal hot flashes. Based on guidance reflected in the meeting minutes, Depomed plans to conduct a single additional pivotal Phase 3 trial evaluating Serada for the treatment of menopausal hot flashes.

20 Jan 2010

Dopamine replacement therapy causes brain dysfunction in patients with Parkinson disease, study says

People with Parkinson's Disease are more likely to display abnormal social behaviour and make poor decisions in ambiguous circumstances if they are pathological gamblers, according to research in the January issue of the European Journal of Neurology.

18 Jan 2010

Epilepsy News and Research

Latest Epilepsy News and Research

Project Lifesaver International, Xanboo to offer medical facilities to help people with cognitive disorder

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

Immigrants may be healthier than long-term residents

FDA approves Xiaflex drug for treatment of Dupuytren's contracture

Phase 2a clinical trial results of VX-809 in patients with CF announced

Ambassadors of Purple selected to help promote Purple Day for Epilepsy

FDA approves Taro Pharmaceutical Industries' levetiracetam tablets ANDA

Researchers explore how brain circuitry and learning changes over time

Government cracks down on drug marketing

GlaxoSmithKline's Lamictal XR Extended-Release Tablets receive FDA approval

Researchers use sophisticated brain-imaging techniques to predict Alzheimer's before symptoms appear

UCLA researchers predict brain's progression to Alzheimer's before symptoms are visible

UCLA's non-invasive pre-surgical testing approach leads to seizure-free surgical outcome in TSC patients

Patients with epilepsy who take Ginkgo herbal medicines face increased risk of seizures

Sepracor's STEDESA NDA: FDA extends PDUFA action date

Large research gap exists in effectiveness, mechanism and safety of drugs in children

US PTO grants new allowances to intellectual property covering Neurologix' GAD based delivery systems

Depomed plans additional Serada Phase 3 trial for treatment of menopausal hot flashes

Dopamine replacement therapy causes brain dysfunction in patients with Parkinson disease, study says

Fast Facts - Everything there is to know about epilepsy eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Epilepsy News and Research

Latest Epilepsy News and Research

Fast Facts - Everything there is to know about epilepsy eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in